Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas

Bone Marrow Transplantation volume 49, pages 1475–1480 (2014)Cite this article

Subjects

A Corrigendum to this article was published on 03 December 2014

This article has been updated

Abstract

Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC >0.5 × 10e9/L and transfusion independent plt count >20 × 10e9/L was 20 days (range 14–38) and 26 days (range 14–395). The probability to reach ANC >0.5 × 10e9/L at 30 days was 87% and transfusion independent plt count >20 × 10e9/L at 100 days was 87%. The cumulative incidence of grade 2–4 acute GVHD (aGVHD) was 25.6% (95% confidence interval (CI): 12.9–38.3%) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2% (95% CI: 0–12.4%). The median follow-up is 20.6 months (range 12–54), and the projected 2-year OS and PFS were 71 and 63%. The relapse rate was 18.7% (95% CI: 7.6–29.8%) and the median time to relapse was 4.4 months (range 1.1–8.3). At 2 years, cumulative incidence of NRM was 16.3% (95% CI: 5.9–26.8%). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Change history

  • 03 December 2014

    This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue.

References

  1. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologus bone marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet 1993; 341: 1051–1054.

    Article  CAS  Google Scholar 

  2. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic SCT for relapsed chemosensitive Hodgkin’s disease: a randomized trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  Google Scholar 

  3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1548.

    Article  CAS  Google Scholar 

  4. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462–4469.

    Article  CAS  Google Scholar 

  5. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106–113.

    Article  CAS  Google Scholar 

  6. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    Article  CAS  Google Scholar 

  7. Robinson SP., Goldstone AH, Mackinnon S, Carella A, Russell N, Ruiz de Elvira C et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working party of the european group for blood and bone marrow transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  Google Scholar 

  8. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941.

    Article  Google Scholar 

  9. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011; 29: 971–978.

    Article  CAS  Google Scholar 

  10. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic SCT in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    Article  CAS  Google Scholar 

  11. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative SCT is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183.

    Article  Google Scholar 

  12. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic SCT for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    Article  Google Scholar 

  13. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic SCT following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  Google Scholar 

  14. Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M et al. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Haematol 2007; 78: 322–329.

    Article  CAS  Google Scholar 

  15. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic SCT after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma Results of the HDR-ALLO study- a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310–317.

    Article  Google Scholar 

  16. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation CY. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  Google Scholar 

  17. Luznik L, Engstrom LW, Iannone R, Fuchs EJ . Posttransplantation CY facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002; 8: 131–138.

    Article  CAS  Google Scholar 

  18. Gordon M Y, Goldman JM, Gordon-Smith EC . 4-HydroperoxyCY inhibits proliferation by human granulocytemacrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 1985; 9: 1017–1021.

    Article  CAS  Google Scholar 

  19. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

  20. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    Google Scholar 

  21. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  Google Scholar 

  22. Chakraverty R, Mackinnon S . Allogeneic transplantation for lymphoma. J Clin Oncol 2011; 29: 1855–1863.

    Article  Google Scholar 

  23. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.

    Article  CAS  Google Scholar 

  24. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  Google Scholar 

  25. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489–500.

    Article  Google Scholar 

  26. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63–72.

    Article  CAS  Google Scholar 

  27. Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012; 97: 1523–1531.

    Article  CAS  Google Scholar 

  28. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ et al. High risk of graft failure in patients with anti-hla antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 88: 1019–1024.

    Article  CAS  Google Scholar 

  29. Luznik L, Jones RJ, Fuchs EJ . High-dose CY for graft-versus-host disease prevention. Curr Opin Hematol 2010; 17: 493–499.

    Article  CAS  Google Scholar 

  30. Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279–1287.

    Article  Google Scholar 

  31. Tuve S, Gayoso J, Scheid C, Radke J, Kiani A, Serrano D et al. Haploidentical bone marrow transplantation with post-grafting CY: multicenter experience with an alternative salvage strategy. Leukemia 2011; 25: 880–883.

    Article  CAS  Google Scholar 

  32. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 256–263.

    Article  Google Scholar 

  33. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554–563.

    Article  Google Scholar 

  34. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN et al. Unrelated donor reduced-intensity allogeneic hematopoietic SCT for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15: 109–117.

    Article  Google Scholar 

  35. Kusumi E, Kami M, Kanda Y, Murashige N, Kishi Y, Suzuki R et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005; 36: 205–213.

    Article  CAS  Google Scholar 

  36. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418–425.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr FB Petersen, SLC, Utah, USA for critical lecture and suggestions.

Author information

Author notes

  1. D Blaise and A Santoro: These authors contributed equally to this work.

Authors and Affiliations

  1. Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy

    L Castagna, S Bramanti, L Giordano, B Sarina, E Mauro, L Morabito, M Balzarotti, C C Stella, E Brusamolino & A Santoro

  2. Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France

    L Castagna, S Furst, R Crocchiolo, R Bouabdallah, D Coso, F Broussais, J El-Cheikh & D Blaise

Authors
  1. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Bramanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Sarina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Mauro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Morabito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Balzarotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F Broussais
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J El-Cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C C Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E Brusamolino
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Castagna.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castagna, L., Bramanti, S., Furst, S. et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant 49, 1475–1480 (2014). https://doi.org/10.1038/bmt.2014.197

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.197

This article is cited by

Search

Advanced search

Quick links